Zacks Investment Research cut shares of Avadel Pharmaceuticals (NASDAQ:AVDL) from a hold rating to a sell rating in a research report sent to investors on Tuesday morning, Zacks.com reports.

According to Zacks, “Avadel Pharmaceuticals plc is a specialty pharmaceutical company. Its product pipeline consists of hospital and paediatrics. Hospital segment provides Bloxiverz(R), Vazculep(R) and Akovaz(TM). Paediatrics segment provides Karbinal (TM) ER, AcipHex(R) Sprinkle and Flexichamber(TM). The company operates primarily in Ireland, USA and France. Avadel Pharmaceuticals plc, formerly known as Flamel Technologies SA, is headquartered in Lyon, France. “

A number of other research firms also recently issued reports on AVDL. LADENBURG THALM/SH SH downgraded shares of Avadel Pharmaceuticals from a buy rating to a neutral rating in a research note on Friday, February 8th. ValuEngine raised shares of Avadel Pharmaceuticals from a sell rating to a hold rating in a research note on Wednesday, January 2nd. Finally, Laidlaw set a $2.00 price target on shares of Avadel Pharmaceuticals and gave the company a hold rating in a research note on Monday, March 18th. Two research analysts have rated the stock with a sell rating and five have assigned a hold rating to the stock. Avadel Pharmaceuticals currently has a consensus rating of Hold and a consensus price target of $5.08.

AVDL stock opened at $1.15 on Tuesday. Avadel Pharmaceuticals has a one year low of $1.11 and a one year high of $7.97. The company has a current ratio of 3.25, a quick ratio of 3.13 and a debt-to-equity ratio of 41.63. The firm has a market capitalization of $42.56 million, a PE ratio of -0.58 and a beta of 1.78.

Avadel Pharmaceuticals (NASDAQ:AVDL) last released its earnings results on Friday, March 15th. The company reported ($0.46) EPS for the quarter, topping the consensus estimate of ($0.52) by $0.06. Avadel Pharmaceuticals had a negative net margin of 92.29% and a negative return on equity of 126.79%. The firm had revenue of $20.92 million for the quarter. On average, equities research analysts predict that Avadel Pharmaceuticals will post -1.39 EPS for the current year.

Institutional investors have recently added to or reduced their stakes in the stock. HRT Financial LLC purchased a new stake in Avadel Pharmaceuticals during the fourth quarter valued at $33,000. Wedbush Securities Inc. purchased a new stake in shares of Avadel Pharmaceuticals in the first quarter valued at $51,000. Paloma Partners Management Co purchased a new stake in shares of Avadel Pharmaceuticals in the fourth quarter valued at $59,000. Millennium Management LLC purchased a new stake in shares of Avadel Pharmaceuticals in the fourth quarter valued at $189,000. Finally, Highbridge Capital Management LLC purchased a new stake in shares of Avadel Pharmaceuticals in the fourth quarter valued at $253,000. 53.43% of the stock is currently owned by institutional investors.

Avadel Pharmaceuticals Company Profile

Avadel Pharmaceuticals plc develops and commercializes pharmaceutical products primarily for treating urology and sleep medicines in the United States, France, and Ireland. Its commercial products that are used in the hospital setting include Bloxiverz, a drug used in the operating room for the reversal of the effects of non-depolarizing neuromuscular blocking agents after surgery; Vazculep, a phenylephrine hydrochloride injection that is used for the treatment of hypotension occurring in the setting of anesthesia; and Akovaz, an ephedrine sulfate injection for treating hypotension, as well as Noctiva for treating nocturia due to nocturnal polyuria.

Featured Story: Trading Penny Stocks

Get a free copy of the Zacks research report on Avadel Pharmaceuticals (AVDL)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Avadel Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avadel Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.